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ABSTRACT
Background: There are very few data about the mutational profile of families 
at-risk for hereditary breast and ovarian cancer (HBOC) from Latin America (LA) and 
especially from Brazil, the largest and most populated country in LA.
Results: Of the 349 probands analyzed, 21.5% were BRCA1/BRCA2 mutated, 
65.3% at BRCA1 and 34.7% at BRCA2 gene. The mutation c.5266dupC (former 
5382insC) was the most frequent alteration, representing 36.7% of the BRCA1 
mutations and 24.0% of all mutations identified. Together with the BRCA1 
c.3331_3334delCAAG mutation, these mutations constitutes about 35% of the 
identified mutations and more than 50% of the BRCA1 pathogenic mutations. 
Interestingly, six new mutations were identified. Additionally, 39 out of the 44 
pathogenic mutations identified were not previously reported in the Brazilian 
population. Besides, 36 different variants of unknown significance (VUS) were 
identified. Regarding ancestry, average ancestry proportions were 70.6% European, 
14.5% African, 8.0% Native American and 6.8% East Asian.
Materials and methods: This study characterized 349 Brazilian families at-risk 
for HBOC regarding their germline BRCA1/BRCA2 status and genetic ancestry. 
Conclusions: This is the largest report of BRCA1/BRCA2 assessment in an at-
risk HBOC Brazilian population. We identified 21.5% of patients harboring BRCA1/
BRCA2 mutations and characterized the genetic ancestry of a sample group at-risk for 
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INTRODUCTION
Breast cancer (BC) constitutes the leading cause of 
cancer mortality among Brazilian women. According to the 
Brazilian National Cancer Institute (INCA), the number 
of new BC cases expected in 2014 was 57,120. A higher 
incidence occurs in Southeastern Brazil, with an estimated 
risk of 71 new cases/year per 100,000 women [1].
It is estimated that 5 to 10% of the BC cases are 
hereditary [2, 3]. Therefore, in Brazil, approximately 
6,000 new cases of hereditary BC are expected yearly, 
which is alarming both for its numerical proportions, and 
for the fact that most of these tumors are not recognized as 
from an hereditary origin [1, 2].
In Brazil, there are few services specialized in 
identifying and monitoring families at-risk for hereditary 
cancer. These services are mainly concentrated in capital 
cities of some Brazilian states, limiting or at least hindering 
the access of a great share of the population living in more 
remote areas [4–6]. Thus, data on BC familial aggregates 
are still scarce in Brazil. The main studies published so 
far involve i) specific populations, such as young women 
with BC [7]; or ii) regions and/or specific gene mutations, 
with most studies focusing their analysis on the founder 
mutations at BRCA1/BRCA2 genes [7–13].
Genetic ancestry
The ethnic substructure of the population is an 
important factor that can influence the incidence, prognosis 
and mortality of BC. A large body of evidence suggested an 
inverse correlation between low incidence of BC and high 
rates of mortality among African-American women when 
compared with Caucasian, with the risk of death from BC 
being 67% higher among African-Americans  [14–16]. 
In addition, work developed in Mexico by Fejerman and 
collaborators [17], showed that for every 25% increase in 
European ancestry there was a 20% increase in risk of BC. 
Otherwise, results of a case-control study published by 
Bonilla and collaborators [18] involving 328 Uruguayan 
women showed no evidence that overall genetic ancestry 
differs between BC patients and controls in Uruguay. 
According to Kehdy and collaborators, Brazil 
is a classical model for population genetics studies 
on admixture, since it received several immigration 
waves from diverse European origins during the last 
five centuries. In addition, African slaves arrived to 
Brazil during four centuries, and the geographic origin 
of Brazilian slaves differ from Caribbean and African 
American [19, 20]. However, little is known about the 
genetic ancestry profile in a highly admixed population 
with BC and/or ovarian cancer (OC). In addition, to the 
best of our knowledge, there are no studies characterizing 
the ancestry profile of a cohort at-risk for hereditary BC in 
the Brazilian population. 
Therefore, we characterized a cohort of 349 
families at-risk for hereditary breast and ovary cancer 
(HBOC) from a single institution for the presence of 
germline BRCA1 and BRCA2 mutations, as well as for 
ethnic composition (genetic ancestry) and correlated these 
molecular findings with the clinical and familial history 
of patients.
RESULTS
General characterization
Among the 349 index cases analyzed (following 
criteria described in the “Material and Methods” section), 
97.4% (n = 340) were female and 2.6% (n = 9) were male, 
all with breast and/or OC history. The vast majority of 
probands had BC as the primary tumor (n = 292, 83.7%), 
50 (14.3%) had a history of OC and 7 patients (2.0%) had 
other tumors than BC or OC as primary tumor site (gall 
bladder (n = 2), colorectal (n = 2), melanoma (n = 1), 
prostate (n = 1) and endometrium (n = 1)).
The mean age at diagnosis was 41 years 
(SD = 12, CI: 16–86 years). When categorized, 22.9% (80 
patients) received a cancer diagnosis at an age below 30 
years, 32.1% (n = 112) between 30 and 40 years, 24.9% 
(n = 87) were diagnosed at ages between 40 and 50 years 
old and 20.1% (70 patients) of the probands had their 
primary tumors detected after 50 years old (Supplementary 
Table S1).
The majority of BC types were invasive ductal 
carcinoma (85.2%), followed by intraductal carcinoma 
(7.6%), papillary (3.4%), lobular (3.4%) and medular 
(1.1%) carcinomas. As for OC types, most (74%) were 
serous adenocarcinomas, followed by undifferentiated 
tumors (13%), endometrioid tumors (7%), clear cell tumors 
(2%), mucinous tumors (2%) and peritoneal tumors (2%).
Among the 349 probands, 21.5% were germline 
mutated (n = 75) with 65.3% of them carrying mutations 
in BRCA1 and 34.7% in the BRCA2. When segregating 
mutated patients according to primary tumor site, 20.5% of 
patients with BC were mutated (60 cases) being 63.3% of the 
mutations in the BRCA1 gene and 36.7% in BRCA2. Among 
patients whose primary tumor was OC, 30.0% (15 patients) 
presented pathogenic mutations in the BRCA1/BRCA2 genes, 
with the majority (73.3%) being located in BRCA1.
hereditary breast cancer showing once again how admixed is the Brazilian population. 
No association was found between genetic ancestry and mutational status. The 
knowledge of the mutational profile in a population can contribute to the definition 
of more cost-effective strategies for the identification of HBOC families.
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Taking into consideration only mutated patients 
with BC, among those with BRCA1 mutated, 72.7% of the 
tumors were triple negative and 27.3% Luminal A or B1. 
Regarding the BRCA2 mutated patients, 9.1% were triple 
negative, 63.6% Luminal A or B1 and 27.3% Luminal B2. 
For those BRCA1/BRCA2 WT, the majority (52.6%) were 
Luminal A/B1, followed by Luminal B2 (20.8%), triple 
negative (18.2%) and HER2 (8.4%). Lastly, patients with 
a VUS on BRCA1 or BRCA2 had a majority of tumors of 
Luminal A/B1 types (54.7%), followed by triple negative 
(19.3%), Luminal B2 and HER2 (13% each).
When the age at diagnosis was compared with the 
mutational status of BRCA1/BRCA2, it was observed that, 
among the group with germline mutations in BRCA1, 
the mean age at diagnosis was 42.1 years (SD = 11.1, 
CI = 23–77 years) and for the group with BRCA2 
mutations, the mean age was 44.7 years (SD = 11.5, 
CI = 26–67 years) (Supplementary Table S1 and 
Supplementary Figure S1).
Cancer family history 
Among the 349 families evaluated, 85 (24.5%) 
reported the presence of at least one case of OC among 
first, second or third degree relatives (or in the proband 
itself), 26 (7.5%) had bilateral breast cancer (BBC), 
11 families (3.2%) reported cases of male BC, and 18 
families (5.2%) had history of pancreatic cancer.
We observed an average of three generations 
affected by cancer (SD = 5), and 5 cancer cases per 
family (SD = 6), with a mean of 3 BC cases (SD = 5). 
When considering mutated families, the average of BC 
among cases with BRCA1 germline mutations was 2.8 
(SD = 1.8), while for BRCA2 mutated cases this mean was 3.4 
(SD = 3.0).
There was a statistically significant difference in 
the distribution of BBC cases according to the status 
of BRCA1/BRCA2 mutations. When the analysis was 
stratified by gene, it was observed that the presence 
of BBC was associated with the presence of germline 
mutations in BRCA1 (p = 0.002), with 8/49 families 
with BRCA1 mutation presenting BBC cases in the 
family.
Mutational profile
Among the 349 index cases included in the study, 75 
(21.5%) showed pathogenic germline mutations in BRCA1 
(n = 49) or BRCA2 (n = 26) (Table 1). No patient carrying 
more than one pathogenic variant was identified. The 
distribution of the different types of mutations (missense, 
nonsense, frameshift, splicing and rearrangements) along 
the exons as well as its frequency are shown in Figure 1 
and Supplementary Figure S2 respectively. 
Among the mutated patients, 60 had a personal 
history of BC and 15 of OC. About the BC with a 
BRCA1 mutation, the great majority were invasive 
ductal carcinomas. For BRCA2 mutated patients, 82% 
were invasive ductal carcinomas, 14% lobular invasive 
carcinomas and 4% were medular tumors. Regarding OC 
patients with a BRCA1 mutation, 67% were high grade 
serous adenocarcinoma, and 33% were undifferentiated. 
For the BRCA2 mutated, the predominant pathology 
were also the serous adenocarcinoma (50%), followed by 
one case of peritoneal tumor and one of undifferentiated 
ovarian tumor.
For BRCA1, 21 different pathogenic mutations were 
identified and one of those was present in 18 different 
families, representing 36.7% of the BRCA1 mutated 
families: the founder mutation c.5266dupC, previously 
known as 5382insC, in exon 20 of BRCA1 gene. The 
second most common mutation (shared by 8 families) was 
the frameshift alteration c.3331_3334delCAAG in exon 
11 of BRCA1. These mutations were identified in families 
coming from different Brazilian regions: 64% from 
Southeast, 28% from Central-West and 8% came from the 
North region of the Brazilian territory.
Twenty-two distinct mutations were identified in 
BRCA2. The only change shared by more than two families 
was the frameshift mutation c.2808_2811delACAA in 
exon 11 of this gene, present in three families. Among the 
identified mutations, two were rearrangements: a deletion 
of exons 5 to 7 at BRCA1 identified by MLPA analysis 
and an Alu insertion at BRCA2 exon 3, identified by a 
mutation-specific PCR.
An association between the presence of c.5266dupC 
mutation and the occurrence of BBC was observed: 22.7% 
of families with this mutation had BBC, in the proband 
(16.7%) or in the family (11.1%) (OR: 3.987, 95% 
CI, 1.210–13.137, p = 0.016). Additionally, there was 
an association between the presence of this mutation 
and the development of OC (OR: 3.2, 95% CI, 1.1–9.0) 
(p = 0.023).
Six new mutations were identified (not described 
in the HGMD, BIC, UMD and ClinVar databases): 2 
in BRCA1 (c.1962dupG and c.5161delC) and four in 
BRCA2 (c.5158_5159insA, c.5216dupA, c.7987delG and 
c.8711delT). All new mutations identified are frameshift 
alterations and lead to the formation of an altered and 
probably non-functional protein. Besides, 39 out of the 44 
pathogenic mutations identified in our study (88.6%) were 
not previously reported in the Brazilian population.
Regarding missense variants, there was an extensive 
review of databases and in silico analysis, in order 
to classify those alterations according to its possible 
pathogenicity. As shown in Table 2, there is a large 
inconsistency among the databases considered for a large 
proportion of the variants analyzed. In addition, data 
regarding the frequency with which the change has been 
identified (number of families with the given alteration) 
and the co-segregation with proven pathogenic variants 
is reported. As detailed in Table 3, five variants were 
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Table 1: Germline mutations identified (pathogenic)
Mutation Mutated Gene 
Number 
of 
families
Mutation 
Type
Tumors in index 
patient, age at onset*
Number 
of BC 
cases in 
relatives*
Number 
of OC 
cases in 
relatives*
c.65T>C p.Leu22Ser BRCA1 1 Missense Ovarian, 55 0 0
c.181T>G  p.Cys61Gly BRCA1 1 Missense Breast, 59 5 1
c.188T>A p.Leu63Ter BRCA1 1 Nonsense Breast, 26 4 0
c.470_471delCT 
p.Ser157Ter
BRCA1 1 Missense Breast, 43 5 0
c.1088delA 
p.Asn363Ilefs*11
BRCA1 1 Frameshift Breast, 36 2 0
c.1687C>T p.Gln563Ter BRCA1 2 Nonsense Breast, 29; Breast, 48 4; 3 0; 0
c.1912delG 
"p.Glu638Asnfs*13"
BRCA1 1 Frameshift Breast, 53 3 0
c.1962dupG 
p.Tyr655Valfs*18
BRCA1 1 Frameshift Breast, 34 3 0
c.2405_2406delTG  
p.Val802Glufs*7
BRCA1 1 Frameshift Breast, 35 2 0
c.3239T>A p.Leu1080Ter BRCA1 1 Nonsense Breast, 31 1 0
c.3331_3334delCAAG  
p.Q1111Nfs*5
BRCA1 8 Frameshift Breast, 39; Ovarian, 32; 
Breast, 32; Breast, 46; 
Breast, 47; Breast, 30; 
Ovarian, 54; Ovarian, 53
2; 1; 4; 4; 
3; 5; 0; 0
0; 0; 1; 0; 2; 
0;0; 0
c.3764dupA 
p.Asn1255Lysfs*11
BRCA1 1 Frameshift Breast, 35 3 0
c.3916_3917delTT  
p.Leu1306Aspfs*23
BRCA1 2 Frameshift Ovarian, 52; breast, 32 3; 1 2; 0
c.4165_4166delAG   
p.Ser1389Ter
BRCA1 1 Frameshift Breast, 33 2 0
c.4357+1G>C BRCA1 1 Splicing Breast, 47 3 0
c.4964_4982del19 
p.Ser1655Tyrfs*16
BRCA1 1 Frameshift Breast, 29 2 0
c.5030_5033delCTAA 
p.Thr1677Ilefs*2
BRCA1 1 Frameshift Breast, 40 4 0
c.5161delC 
p.Gln1721Serfs*9
BRCA1 1 Frameshift Breast, 45 1 1
c.5251C>T p.Arg1751Ter BRCA1 1 Nonsense Breast, 23 4 1
c.5266dupC 
p.Gln1756Profs*74
BRCA1 18 Frameshift Breast, 36; Breast, 63; 
Ovarian, 77; Breast, 36; 
Breast, 44; Ovarian, 54; 
Ovarian, 47; Ovarian, 
53: Breast, 31; Ovarian, 
47; Breast, 41; Ovarian, 
49; Breast, 33; Breast, 
42; Breast, 37; Breast, 
28; Breast, 28; Breast, 47
8; 4; 2; 2; 
4; 2; 0; 4; 
2; 0; 5; 0; 
6; 3; 2; 4; 
1; 4
0; 0; 0; 1; 0; 
0; 0; 1; 0; 0; 
0; 0; 1; 0; 0; 
0; 0; 0
c.5444G>A p.Trp1815Ter BRCA1 1 Nonsense Breast, 45 6 0
c.5463_5464insT 
p.His1822Serfs*7
BRCA1 1 Frameshift Breast, 50 4 1
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identified in patients carrying pathogenic mutations. The 
variants c.811G>A (BRCA1) and c.8187G>T (BRCA2) 
were identified in a patient carrying the pathogenic 
mutation c.8023A>G (p.Ile2675Val) at the BRCA2 gene. 
In addition, the alteration c.8351G>A (BRCA2) was 
identified in two patients and one of them is carrier of 
the mutation p.Arg337His at TP53 gene (this patient also 
has the variant c.7469T>C, at BRCA2 gene). Lastly, the 
alteration c.7448G>A (BRCA2) was identified in a patient 
carrying the BRCA1 mutation c.1687C>T(p.Gln563Ter).
Furthermore, three patients harbor more than 
one variant. One of them is carrier of the c.7469T>C 
(BRCA2) and c.8351G>A (BRCA2) variants (this patient 
also have the pathogenic mutation p.Arg337His at TP53 
gene as described above); the other have the alterations 
c.4928T>C (BRCA2), and c.8351G>A (BRCA2). In 
addition one patient (with OC at 59 years of age and carrier 
of the pathogenic mutation c.8023A>G (p.Ile2675Val) at 
the BRCA2 gene) has two variants: c.811G>A (BRCA1) 
and c.8187G>T (BRCA2).
The identification of two families with possible 
pathogenic variants (C65 score) in BRCA1 (c.190T>C, 
p.Cys64Arg, c.5509T>C and p.Trp1837Arg) as well 
as three families carrying variants with the same score 
deletion exons 5 to 7 BRCA1 1 Rearrangement Breast, 56 2 1
c.2T>G p.Met1Arg BRCA2 2 Missense Breast, 48; Breast, 43 6; 5 0; 0
c.156_157insAlu BRCA2 1 Rearrangement Breast, 29 2 0
c.658_659delGT 
p.Val220Ilefs*4
BRCA2 1 Frameshift Breast, 49 2 1
c.1138delA 
p.Ser380Valfs*19
BRCA2 1 Frameshift Breast, 49 4 0
c.2808_2811delACAA 
p.Ala938Profs*21
BRCA2 3 Frameshift Breast, 43; Breast, 34; 
Breast, 36
2; 4; 2 0; 0; 0
c.3858_3860delAAA 
p.Lys1286del
BRCA2 1 In frame 
deletion
Breast, 49 2 0
c.4284dupT  
p.Gln1429Serfs*9
BRCA2 1 Frameshift Ovarian, 65 0 0
c.5073dupA 
p.Trp1692Metfs*3
BRCA2 2 Frameshift Ovarian, 63; Breast, 31 1; 1 0; 1
c.5158_5159insA 
p.Ser1720Tyrfs*7
BRCA2 1 Frameshift Breast, 51 1 1
c.5216dupA p.Tyr1739Ter BRCA2 1 Frameshift Bresat, 36 3 0
c.5682C>G p.Tyr1894Ter BRCA2 1 Nonsense Breast, 44 6 0
c.5857G>T p.Glu1953Ter BRCA2 1 Nonsense Ovarian, 56 3 1
c.6405_6409delCTTAA 
p.Asn2135Lysfs*2
BRCA2 2 Frameshift Breast 41; Breast, 48 7; 4 0; 0
c.6611delC 
p.Pro2204Leufs*2
BRCA2 1 Frameshift Breast, 46 3 0
c.7180A>T p.Arg2394Ter BRCA2 1 Nonsense Breast, 34 1 0
c.7987delG  
p.Glu2663Lysfs*10
BRCA2 1 Frameshift Breast, 31 7 0
c.8023A>G p.Ile2675Val BRCA2 1 Missense Ovarian, 59 3 0
c.8488-1G>A BRCA2 1 Splicing Breast, 26 1 0
c.8711delT 
p.Leu2904Leufs*4
BRCA2 1 Frameshift Breast, 30 4 1
c.9382C>T p.Arg3128Ter BRCA2 1 Nonsense Breast, 53 3 1
c.9401delG 
p.Gly3134Alafs*29
BRCA2 1 Frameshift Breast, 35 5 0
Bold indicates new mutations identified in the present study.
*cases where more the one family carries the same mutation are separated by “;”.
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in BRCA2 (c.4585G>A, p.Gly1529Arg; c.6935A>T, 
p.Asp2312Val, c.7994A>G and p.Asp2665Gly) was 
possible using the AlignGVGD program. The probands 
of four out of these 5 families have had BC at very early 
ages (ages between 27 and 30 years as can be seen in 
details at Table 3). The only family with tumors at more 
advanced ages among those with variants classified 
as C65 is the family with the variant c.7994A>G at 
BRCA2 gene, where the proband had BC at 60 years 
old. However, this woman has two relatives with BC (at 
35 and 66 years respectively) and one with OC (age at 
diagnosis unknown).
An alteration located in a splicing region in the 
BRCA1 gene (variant c.5153-2A>C) was also identified 
in a patient with BC at 28 years old. However, since 
there was no previous report in the literature, as well 
as no functional study performed supporting their non-
functionality, this variant was not considered as proven 
pathogenic. Similarly, the BRCA2 variants (missense) 
c.6554C>T (p.Ala2185Val), c.6988A>G (p.Ile2330Val) 
and c.8755G>T (p.Gly2919Cys) have not been previously 
described in the literature and given the lack of 
information about their biological impact they have been 
“provisionally” considered VUS. However it is important 
to highlight that the patient with the variant c.6988A>G 
(BRCA2) had a personal history of BBC at 24 years of age 
and 2 relatives with BC, raising strong suspicion about 
its pathogenicity (although classified as benign by the in 
silico tools used).
Two other identified  variants that call our attention 
were: (i) the c.5096G>A (BRCA1), identified in a family 
without BC history (proband with OC at 44 and one 
relative with OC), which was the only variant identified 
in families with cancer history exclusive of OC and (ii) 
the in frame deletion c.5425_5430delGTTGTG, due to 
the severity of the family history (proband with BC at 36 
years old and 7 cases of BC among first, second and third 
degree relatives). In the same way, two families with the 
alteration c.6347A>G (BRCA2) had probands with BC at 
38 and 26 years respectively, and 4 cases of BC in each 
family were reported. 
For the 274 index cases with no identified BRCA1/
BRCA2 germline mutation, test for the TP53 gene 
was performed, which detected pathogenic mutation 
in 9 patients (data not shown). All these 9 families had 
probands with BC diagnosed before the age of 50 (varying 
from 27 to 48 years) and at least one first or second 
degree relative with BC. All 9 families are carriers of the 
Brazilian founder mutation p.Arg337His (exon 10 of TP53 
gene) [21].
Ancestry
We further performed genetic ancestry assessment 
on 341 of the 349 participants (Figure 2) using 46 
ancestry-informative markers. Although overall ancestry 
estimates computed with Admixture and Structure 
algorithms were similar, for simplicity we will refer only 
to the former one. Average ancestry proportions in our 
group were 70.6% European, 14.5% African, 8.0% Native 
American and 6.8% East Asian. 
There was no statistically significant difference in 
the ancestry profile of WT individuals when compared to 
those with germline mutation in BRCA1/BRCA2 genes 
(Supplementary Table S2 and Figure 2). Additionally, 
there is no difference in the ancestry profile between 
BRCA1 and BRCA2 mutated women (p = 0.434).
To verify the association of ancestry with clinical 
characteristics, patients were subdivided according to 
the BRCA1/BRCA2 status: WT or mutated. Among the 
mutated ones (BRCA1 or BRCA2), no association with 
clinico-pathological characteristics and genetic ancestry 
was observed. 
On the other hand, we observed that the African 
ancestry component among individuals without BRCA1/
BRCA2 mutations was associated with higher tumor 
Figure 1: Distribution of the identified mutations along the BRCA1 and BRCA2 genes.
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Table 2: Variants of unknown significance according to 7 databases an 5 in silico prediction 
programs
HGMD BIC LOVD LOVD 
IARC
ClinVar ARUP BRCA 
Share™
Polyphen- 
2
SIFT Align- 
GVGD
MAPP CADD
BRCA1
c.190T>C; p.Cys64Arg Yes VUS Normal RNA 
splicing
N/R conflicting 
data
N/R Causal probably 
damaging
Predict Not 
Tolerated
C65 Not tolerated NC
c.811G>A; p.Val271Met Yes VUS probably 
neutral
N/R VUS N/R N/R possibly 
damaging
Predict Tolerated C0 Not tolerated NC
c.1601A>G; p.Gln534Arg N/R VUS N/R N/R VUS N/R VUS benign Predict Not 
Tolerated
C0 Not tolerated High 
risk
c.1648A>C p.Asn550His Yes VUS probably 
neutral
class 1 conflicting 
data
Class 1 Neutral probably 
damaging
Predict Not 
Tolerated
C0 Tolerated NC
c.3823A>G p.Ile1275Val N/R VUS probably 
neutral
N/R conflicting 
data
N/R Neutral benign Predict Tolerated C0 Tolerated NC
c.4484G>A p.Arg1495Lys VUS yes N/R N/R conflicting 
data
N/R Causal benign Predict Not 
Tolerated
C0 Not tolerated NC
c.5062_5064delGTT; 
p.Val1688del
Yes VUS No splicing 
defect
N/R conflicting 
data
Class 5 Causal NC NCR NC NC NC
c.5096G>A  p.Arg1699Gln Yes VUS probably 
deleterious
N/R conflicting 
data
N/R VUS probably 
damaging
Predict Not 
Tolerated
C35 Not tolerated Medium 
risk
c.5153-2A>C N/R N/R N/R N/R N/R N/R N/R NC NC NC NC NC
c.5425_5430delGTTGTG
N/R VUS N/R N/R VUS N/R N/R NC NC NC NC NC
c.5509T>C; p.Trp1837Arg Yes VUS probably 
deleterious
N/R conflicting 
data
N/R VUS probably 
damaging
Predict Not 
Tolerated
C65 Not tolerated NC
BRCA2
c.223G>C p.Ala75Pro Yes VUS probably 
neutral
class 1 conflicting 
data
Class 1 Neutral probably 
damaging
Predict Not 
Tolerated
C0 Not tolerated NC
c.1798T>C p.Tyr600His N/R VUS N/R N/R conflicting 
data
N/R VUS benign Predict Tolerated C0 Tolerated NC
c.2274 T > G p.Ser758Arg N/R N/R N/R N/R VUS N/R N/R benign Predict Tolerated C0 Not tolerated Low 
risk
c.2350A>G p.Met784His VUS VUS probably 
neutral
class 3 N/R Class 3 VUS possibly 
damaging
Predict Not 
Tolerated
C0 Not tolerated NC
c.2503C>T p.Pro835Ser N/R VUS N/R N/R VUS N/R N/R benign Predict Tolerated C0 Tolerated Low 
risk
c.4585G>A p.Gly1529Arg Yes no inconclusive class 1 benign Class 1 Neutral probably 
damaging
Predict Not 
Tolerated
C65 Tolerated NC
c.4681C>A p.His1561Asn N/R VUS N/R N/R conflicting 
data
N/R VUS benign Predict Tolerated C0 Tolerated NC
c.4928T>C p.Val1643Ala N/R VUS inconclusive class 3 conflicting 
data
Class 3 VUS benign Predict Tolerated C0 Tolerated NC
c.5096A>G p.Asp1699Gly N/R VUS N/R N/R VUS N/R N/R benign Predict Tolerated C0 Not tolerated NC
c.5640T>G p.Asn1880Lys Yes VUS probably 
neutral
N/R conflicting 
data
N/R Polymorphism benign Predict Not 
Tolerated
C0 Not tolerated NC
c.6347A>G  p.His2116Arg Yes no N/R N/R benign N/R Neutral possibly 
damaging
Predict Not 
Tolerated
C0 Tolerated NC
c.6412G>T p.Val2138Phe N/R VUS probably 
neutral
N/R conflicting 
data
N/R VUS benign Predict Not 
Tolerated
C0 Tolerated NC
c.6554C>T p.Ala2185Val N/R N/R N/R N/R N/R N/R N/R benign Predict Tolerated C0 Tolerated Low 
risk
c.6935A>T p.Asp2312Val VUS VUS probably 
neutral
N/R VUS N/R VUS probably 
damaging
Predict Not 
Tolerated
C65 Not tolerated NC
c.6988A>G  p.Ile2330Val N/R N/R N/R N/R N/R N/R N/R benign Predict Tolerated C0 Not tolerated NC
c.7017G>C p.Lys2339Asn VUS no N/R N/R conflicting 
data
N/R Likely neutral benign Predict Tolerated C0 Not tolerated NC
c.7448G>A  p.Ser2483Asn N/R VUS probably 
neutral
N/R conflicting 
data
N/R VUS benign Predict Tolerated C0 Tolerated Low 
risk
c.7469T>C   p.Ile2490Thr VUS no probably 
neutral
N/R conflicting 
data
N/R VUS benign Predict Tolerated C45 Not tolerated NC
c.7507G>A p.Val2503Ile N/R N/R N/R N/R VUS N/R VUS benign Predict Tolerated C0 Tolerated Low 
risk
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c.7994A>G p.Asp2665Gly VUS no probably 
neutral
class 2 bening Class 2 VUS probably 
damaging
Predict Not 
Tolerated
C65 Not tolerated Low 
risk
c.8187G>T  P.Lys2729Asn VUS VUS probably 
neutral
class 1 conflicting 
data
Class 1 VUS probably 
damaging
Predict Not 
Tolerated
C35 Not tolerated Low 
risk
c.8351G>A p.Arg2784Gln Yes VUS probably 
deleterious
N/R VUS N/R VUS probably 
damaging
Predict Not 
Tolerated
C35 Not tolerated NC
c.8755G>T  p.Gly2919Cys N/R N/R N/R N/R N/R N/R N/R probably 
damaging
Predict Not 
Tolerated
C15 Tolerated Low 
risk
c.9235G>A  p.Val3079Ile N/R VUS probably 
neutral
class 1 conflicting 
data
Class 1 VUS possibly 
damaging
Predict Tolerated C0 Tolerated NC
c.9730G>A  p.Val3244Ile N/R no N/R N/R conflicting 
data
N/R VUS Benign Predict Tolerated C0 Tolerated NC
NR: not reported; NC: not calculated; VUS: variant of unknown significance.
Align-GVGD scores: C0: neutral, C15: low risk of protein function alteration, C25: low to medium risk of protein function alteration, C35: medium to high risk of protein function alteration, C45: high risk 
of protein function alteration, C55: high risk of a pathogenic protein function alteration, C65: pathogenic protein function alteration. 
Table 3: Information regarding tumor history, frequency and segregation of the variants of 
unknown significance
NOF Co-
segregation
Tumors in index patient, 
age at onset*
Number of 
BC cases in 
relatives*
Number of OC 
cases in relatives*
BRCA1
c.190T>C; p.Cys64Arg 1 no Breast, 30 2 0
c.811G>A;  p.Val271Met 1 yes Ovarian, 59 3 1
c.1601A>G; p.Gln534Arg 1 no Breast, 51 5 0
c.1648A>C p.Asn550His 1 no Breast, 49 4 0
c.3823A>G p.Ile1275Val 1 no Breast, 43 1 0
c.4484G>A p.Arg1495Lys 1 no Breast, 26 3 0
c.5062_5064delGTT; 
p.Val1688del
1 no Breast, 33 2 0
c.5096G>A p.Arg1699Gln 1 no Ovarian, 44 0 1
c.5153-2A>C 1 no Breast, 28 1 0
c.5425_5430delGTTGTG 1 no Breast, 36 7 0
c.5509T>C; p.Trp1837Arg 1 no Breast, 28 0 0
BRCA2
c.223G>C p.Ala75Pro 2 no Breast, 20; Breast, 54 1;3 0;0
c.1798T>C p.Tyr600His 1 no Ovarian, 46 0 0
c.2274 T > G  p.Ser758Arg 1 no Breast, 35 2 0
c.2350A>G p.Met784His 1 no Breast, 55 3 0
c.2503C>T p.Pro835Ser 2 no Breast, 54 2 0
c.4585G>A p.Gly1529Arg 1 no Breast, 27 2 0
c.4681C>A p.His1561Asn 1 no Breast, 28 1 0
c.4928T>C p.V1643A 1 no Breast, 40 2 0
c.5096A>G p.Asp1699Gly 1 no Breast, 24 1 0
c.5640T>G p.Asn1880Lys 2 no Breast, 27; Breast, 36 1;2 0;0
c.6347A>G p.His2116Arg 3 no Breast, 38; Breast, 26; 
Breast, 44
4;1;4 0;0;?
c.6412G>T p.Val2138Phe 1 no Breast, 49 2 0
c.6554C>T  p.Ala2185Val 1 no Breast, 31 2 0
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grade (p = 0.008). Furthermore, we found out that 
when the African component increases in an individual, 
the probability of BBC decreases (p = 0.005) and 
the number of cancer cases in the family increases 
(p = 0.04).  
In 15 out of 18 patients with c.5266dupC mutation 
in the BRCA1 gene, the European ancestry component 
was predominant (over 69%) (Figure 3). There was 
no statistically significant difference in the ancestry 
component of patients carrying the c.5266dupC mutation 
vs. those with other BRCA1/BRCA2 mutations. For 
one patient, there was a similar balance between the 
Amerindian (0.482) and European (0.478) components 
(Figure 3). In another family, there was a similar 
distribution among three components: 0.387 for the 
European, 0.280 for the Amerindian and 0.261 for the 
African component (Figure 3). 
DISCUSSION
The present work is the largest study analyzing 
the BRCA1/BRCA2 germline mutation frequencies in 
the Brazilian population, with a prevalence of 21.5% 
of deleterious mutations, being 13.6% new mutations 
(not described in the literature) and 88.6% of them 
never described in the Brazilian population. Although 
it represents the data from a single Institution, the BCH 
receives patients from all over Brazil. In this particular 
study, the majority (71.6%) came from the Southeast region 
of Brazil, followed by the Central-West (18.3%), North 
(7.2%), and the Northeast and South regions (1.4% each), 
covering 16 Brazilian States. Moreover, given the highly 
admixed Brazilian population, and the potential impact of 
the presence of founder mutations, this study presents a 
characterization of the genetic ancestry of this cohort.
c.6935A>T p.Asp2312Val 1 no Breast, 28 1 0
c.6988A>G  p.Ile2330Val 1 no Breast, 24 2 0
c.7017G>C p.Lys2339Asn 2 no Ovarian, 33; Breast, 74 2;1 1;0
c.7448G>A p.Ser2483Asn 1 yes Breast, 29 4 0
c.7469T>C p.Ile2490Thr 10 yes Breast, 29; Breast, 39; 
Breast, 29; Breast, 38; 
Breast, 43;       Breast, 40; 
Breast, 37; Breast, 41; 
Bresat, 61; Breast, 29;
1;3;1;1;4;2;6;1;3;1 0;0;0;0;0;0;0;0;0;0
c.7507G>A p.Val2503Ile 1 no Breast, 37 2 0
c.7994A>G p.Asp2665Gly 1 no Breast, 60 2 1
c.8187G>T P.Lys2729Asn 1 yes Ovarian, 59 3 0
c.8351G>A  p.Arg2784Gln 2 yes Breast, 41; Breast,  40 1;2 0;0
c.8755G>T p.Gly2919Cys 1 no Breast, 32 0 0
c.9235G>A p.Val3079Ile 1 no Breast, 55 2 0
c.9730G>A p.Val3244Ile 2 no Ovarian, 33; Breast, 74 2;1 1;0
*cases where more the one family carries the same mutation are separated by “;”.
Figure 2: Ancestral profile of the studied patient group showing individual ancestry estimates according to mutational 
status. BRCA1 mutated (left), BRCA2 mutated (centre) and BRCA1/BRCA2 WT (right).
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We observed a frequency of 21.5% BRCA1/BRCA2 
mutated patients, with most of the mutations located in the 
BRCA1 gene (65.3%). Other than the results reported in 
this manuscript there are just a few studies on the subject 
carried out in the Brazilian population [7–13, 22–24] and 
they are depicted in  Table 4.
As shown in Table 4, there are only three studies 
involving the analysis of the entire coding region of the 
BRCA1/BRCA2: the study published by Carraro and 
colleagues in 2013 [24] that examined 54 women with BC 
diagnosed before the age of 35, the study published by 
Silva et al. in 2014 [23] which included 120 women and 
ours, that analyzed 349 index cases of suspected HBOC 
families. Although the inclusion criteria may differ, the 
three studies identified a similar percentage of mutations, 
20.4%, 22.5% and 21.5% respectively. Other studies 
involving larger sample sizes were performed, however 
they investigated the presence of specific regions of the 
BRCA1/BRCA2 genes or specific mutations (founder 
mutations), and the percentage of mutations identified 
were quite low [8, 11].
The fraction of pathogenic mutations identified in 
our study is in accordance with recent published studies 
all over the world. A study conducted by Peixoto et al. 
analyzed the entire BRCA1/BRCA2 coding region of 
524 Portuguese patients and identified 112/524 families 
(21.4%) with pathogenic mutation [25]. Kang and 
collaborators analyzed 2403 Korean index patients and 
found that the prevalence of BRCA mutations in BC 
patients with a family history of breast/ovarian cancer was 
22.3% [26]. Churpek and colleagues [27] studied a group 
of 289 African-American women with family history 
of BC and the rate of identified pathogenic mutations 
was 22%. In a similar way, Weitzel and colleagues [28] 
evaluated 746 Hispanics with personal and/or family 
history of breast or OC, and found the presence of BRCA1/
BRCA2 mutations in 25% of them. In Colombia, a study 
conducted by Torres and collaborators found a frequency 
of 24.5% of deleterious BRCA1/BRCA2 mutations in a 
cohort of 53 breast/ovarian cancer families evaluated [29]. 
Finally, data on 10 years of genetic testing (November 
1996 to March 2006) conducted by Myriad Laboratory 
(USA), representing more than 95% of genetic testing for 
BRCA1/BRCA2 genes performed in the United States, not-
selected by breast/ovarian cancer family history, points 
to a frequency of 12.5% identified deleterious mutations 
(5,780 mutated individuals in a total of 46.276 individuals 
consecutively tested) [30].
In the present study we found that, among patients 
with mutated BRCA1, 77.5% had a personal history of BC, 
and 22.4% of OC. Regarding BRCA2, 84.6% had previous 
personal history of BC and 15.4% of OC. This is similar to 
the results recently published by Rebbeck and colleagues 
[31]. Rebbeck´s results show that the proportion of cancer-
affected individuals carrying mutated BRCA1 with BC 
was 72.9%, with OC 18.7% and with a personal history of 
breast and ovarian cancer was 8.4%. Regarding BRCA2, 
86.6% of the mutated patients had BC, 9.6% OC and 3.8% 
presented previous personal history of both tumors.
We observed that two BRCA1 mutations are 
responsible for more than 50% of the mutations identified in 
this gene in our cohort: the c.5266dupC accounting for 36.7% 
of mutations in the BRCA1 gene and for 24% of all mutations 
found in this study and the mutation c.3331_3334delCAAG, 
that represents 16.3% of our BRCA1 mutations and 10.7% 
of the mutations identified. Although the present study is not 
representative of the Brazilian population diversity, the fact 
that i) two mutations account for over 50% of the identified 
mutations and ii) these two alterations were not concentrated 
in only one Brazilian region, may serve as a first approach 
strategy for genetic testing, not only in Brazil, but also in 
countries/services where the financial resources are limited 
and where the public health system or private plans do not 
cover such molecular analysis. If negative results are found 
Figure 3: Ancestry contribute on of c.5266dupC mutated patients. 
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with this initial screening, the analysis of all coding sequence 
of both BRCA1 and BRCA2 is imperative. 
The presence of c.5266dupC mutation was 
associated with an increased risk for OC in our series, 
leading to a three times higher risk than those WT 
individuals for that mutation. Similarly, a study conducted 
in Poland identified that this mutation was present in 57% 
of the mutated OC cases [32].
The c.5266dupC mutation represents about 98–99% 
of the mutations found in Ashkenazi Jews, however it is 
not restricted to these populations. It has been reported as 
having high prevalence in several countries, mainly from 
Central and Eastern Europe [33]. Among the 18 patients 
in our study who are carriers of this mutation, although we 
could not assess the local ancestry of the locus containing 
the BRCA1 c.5266dupC mutation, the European ancestry 
profile was prevalent in 94.4% of cases (17/18 families). 
For 83.3%, the European contribution was higher than 69%. 
In one case, the main contribution was the Amerindian 
followed by the European, demonstrating, once again, the 
wide miscegenation present in the Brazilian population.
Regarding genomic rearrangements, it is known that 
its frequency varies considerably among populations [34]. 
Although common in some populations, representing about 
30% of the mutations identified in BRCA1/BRCA2 genes in 
the Netherlands and Germany [35], large rearrangements 
Table 4: Summary of Brazilian BRCA1 and/or BRCA2 studies
Sample size % of BRCA1 /BRCA2 mutations Selection criteria Genetic test performed Authors, year
47 7 (14.9%) HBOC patients All coding regions of BRCA1 Lourenço, 2004 
31 4 (9.6%) HBOC patients BRCA1 exons 2, 3, 5, 11 and 20 
and BRCA2 exons 10 and 11
Dufloth, 2005  
402 9 (2.3%) BC, irrespective 
to age or family 
history
Four common alterations in 
BRCA1 and BRCA2 (185delAG, 
5382insC and exon 13 6kb 
duplication in BRCA1 and 
6174delT in BRCA2
Gomes, 2007
612 21 (3.4%) HBOC patients BRCA1 exon 11 and BRCA2 
exons 10 and 11 and specific 
founder mutations
Esteves, 2009 
137 7 (5%) non-Ashkenazyi 
HBOC patients
BRCA1 exon 2 (c.68_69del 
mutation), exon 20 (c.5266dup 
mutation) and BRCA2 exon 11 
(c.5946del mutation).
Ewald, 2011 
255 3 (1.2%) Askenazi-jews 
unselected for 
family history of 
cancer
BRCA1 185delAG, BRCA1 
5382insC and BRCA2 6174delT
Dillenburg, 2012 
54 11 (20.4%) BC <35years, 
irrespective to 
family history
All coding regions of BRCA1 
and BRCA2
Carraro, 2013 
106 9 (8.5%) HBOC patients All coding regions of BRCA1 
and common founder mutations 
in the BRCA2
Felix, 2014
120 27 (22.5%) HBOC patients BRCA1/BRCA2 point mutations 
and rearrangements
Silva, 2014 
616 0 (0%) 513 cancer-free 
patients and 103 
OC patients
BRCA1 (c.68_69delAG, 
c.5266dupC, c.181T>G, 
c.4034delA, c.5123C>A) 
and BRCA2 (c.5946delT, 
c.8537_8538delAG, 
4936_4939delGAAA, 
c.156_157insAlu)
Schayek,2015
349 75 (21.5%) HBOC patients All coding regions of BRCA1 
and BRCA2
Present study
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are relatively rare in most populations [34]. In the present 
cohort, although not representative of the entire Brazilian 
population, only two families with rearrangements 
were identified, one case with rearrangement in BRCA1 
(deletion of exons 5–7), and the other with a rearrangement 
in BRCA2 gene, that is regarded as a Portuguese founder 
mutation (c.156_157insAlu in BRCA2), mutation that 
represents about 40% of deleterious germline mutations of 
BRCA1/BRCA2 in Portugal [33, 36, 37].
Concerning the variants with unknown clinical 
significance, we have reported a list of variants identified 
in our study (mostly missense variants), and, we observe 
a lack of consensus about their biological/clinical 
significance among the different existing databases. The 
number of cases tested in our center so far does not allow 
us to classify these variants based on their frequency or 
the co-occurrence of pathogenic mutations (although we 
have identified that five of our identified variants were 
present in individuals carrying pathogenic mutations, 
albeit not in the same gene for 4 of them) . Therefore, 
our strategy consists in in silico analysis, segregation 
studies (which will be conducted in cases where there 
is availability of family members with and without 
cancer) and analysis of available databases. However, the 
analysis of databases has not been instructive in most of 
cases. As an example, the BRCA1 variants c.5509T>C 
and c.5096G>A have been considered pathogenic by 
HGMD, VUS, by BIC and UMD, “probably deleterious” 
by LOVD, and not conclusive by ClinVar (“conflicting 
data”). In the case of BRCA2 variants c.4585G>A and 
c.6347A>G, these are considered to be pathogenic by 
HGMD, without clinical significance by BIC and benign 
by ClinVar. These discrepancies between the databases, 
although “explicable”, given the low prevalence of most 
of these variants, highly hinder the clinical work and the 
subsequent management of patients and their families. 
According to Miller-Samuel and colleagues “The VUS 
can create additional confusion and anxiety for the 
patient and family, and increased uncertainty for the 
clinician responsible for making medical management 
recommendations. Although clinicians are advised not to 
make management decisions based on VUS results, what 
actually happens in real-world clinical practice?” [38]. 
Even though clinician’s decisions cannot be 
made based on VUS, some of our findings called 
our attention and deserve deep investigation. This 
is the case, for example for the age at diagnosis and 
the number of BC seen in the families carrying the 
alterations c.5425_5430delGTTGTG (BRCA1), 
c.6347A>G (BRCA2) and c.1601A>G (BRCA1) (8, 5 and 
6 BC cases respectively), as well as the very early ages at 
diagnosis (24 years old) of the probands with the variants 
c.5096A>G (BRCA2) and c.6988A>G (BRCA2). Given 
the absence of consensus among databases, those families 
should be further evaluated through segregation analysis 
and functional studies. In addition, sequencing using 
other breast/ovarian cancer predisposition genes (high 
and moderate risk already present in commercial panels) 
should also be conducted.
It is also worth observing that the characteristic 
widespread miscegenation of the Brazilian population 
was proven in our sample. Although most of the cases 
analyzed present a major European ancestry component, 
we identified in all cases a contribution from more than 
one ancestor component, often equally distributed. 
Although study participants were from different regions of 
Brazil, we did not identify in this study a difference in the 
ancestry profile associated with the region of origin of the 
participants, which can be due to the high concentration 
of patients from the Southeast Brazilian region. According 
to Kedhy and colleagues [19], the African component in 
individuals of the northeast region of Brazil is of 50%, 
while in the South and Southeast of Brazil, the European 
component exceeds 70%. Still according to Kedhy and 
collaborators, in highly miscegenated Latin American 
populations such as the Brazilian, the frequency and 
distribution of deleterious mutations are determined more 
by the history of its population than for its demographics. 
In Brazil, for example, in 1870, Africans constituted the 
predominant ethnic group, which changed with the arrival 
of about 4 million Europeans during the second half of the 
19th century and the first half of the 20th century. These 
migrations transformed Brazil in a predominantly white 
nation, especially in the South and Southeast regions of 
the country [19]. Nonetheless, although we found a great 
predominance of European ancestry in our sample, all 
individuals (mutated or not) had a greater or lesser extent 
of ancestral profiles admixture and this mixture was not 
correlated with mutational status, mutation type, age at 
diagnosis or type of cancer developed. However, some 
associations or trends could be observed, such as a more 
aggressive cancer behavior (higher grade tumor) in patients 
whose African component was larger. However, these data 
needs to be further validated in a larger sample group.
This study has some limitations, such as the fact 
that other high and moderated BC associated genes were 
not included in the test. In addition, although this is the 
largest Brazilian study involving complete sequencing of 
the genes BRCA1/BRCA2 in a high-risk sample for HBOC 
and correlating the findings with the ancestral profile of 
the population., the cohort analyzed cannot be considered 
representative of the whole Brazilian population and the 
results obtained regarding the lack of association among 
the mutational profile and genetic ancestry should be 
further validated in a bigger cohort. The genotyping of a 
larger sample group with all five Brazilian regions equally 
represented would be very informative.
In conclusion, this is the largest Brazilian study 
involving complete sequencing of the genes BRCA1/
BRCA2 in a high-risk sample for HBOC and correlating 
the findings with the ancestral profile of the population. 
We identified 21.5% of BRCA1/BRCA2 mutated patients, 
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with most of the identified mutations located in the 
BRCA1 gene (65.3%). Among the mutations identified, 
the mutations c.5266dupC and c.3331_3334delCAAG 
constitutes about 35% of the mutations identified in our 
cohort and more than 50% of the BRCA1 mutations. In 
addition, we could not identify any association between 
the ancestry profile and the distribution of BRCA1/BRCA2 
mutations in the analyzed sample. Although genetic 
testing for these genes are already available for almost 
two decades, this test remains a great example of the 
use of human genetic variability in reducing the risk of 
developing cancer.
MATERIALS AND METHODS
Sample population
A total of 349 unrelated individuals at-risk for 
HBOC (with personal and familial history of BC and/or 
OC) were referred from the Oncogenetics Department 
(OD) for genetic testing for BRCA1/BRCA2 genes in the 
period between 2010 and 2014. The OD was established 
in 2010 at the Barretos Cancer Hospital (reference center 
in Brazil for the prevention and treatment of cancer) 
and offers multidisciplinary care and in multiple steps, 
ranging from genetic risk assessment to genetic testing 
for high-risk families identified (Palmero EI, “in press”). 
All families were identified by the OD and fulfilled at 
least one of the following criteria: a) the clinical criteria 
recommended by the National Institute for Health Care 
Excellence (NICE) [39] (for details see Supplementary 
Table S3); b) probability of mutation in BRCA1/BRCA2 
over 20% according to the Myriad prevalence tables 
[40, 41]; c) BC diagnosed below 30 years old; and d) the 
presence of OC in the family. Furthermore, in the families 
where a pathogenic germline mutation was identified, 
mutation-specific predictive genetic test was performed 
for all interested relatives. Confirmation of the cancer 
family history was attempted in all cases by pathology 
and medical reports and/or death certificates. The project 
was approved by the local Ethics in Research Committee.
BRCA1 and BRCA2 mutation screening
Genomic DNA was isolated from peripheral blood 
samples using the QIAamp DNA Blood Mini Kit (Qiagen) 
following the manufacturer’s instructions. All coding 
exons were amplified by multiplex-PCR reactions, as 
described by Costa et al. [42].
After PCR amplification of the BRCA1 
(NM_007294.3) and BRCA2 (NM_00059.3) genes, the 
products were purified (ExoSap-IT - USB), and sequenced 
(BigDye terminator v3.1 - Applied Biosystems). Following 
purification, samples were analyzed in a 3500xL Genetic 
Analyzer (Applied Biosystems). The results were analyzed 
using the SeqScape software (Applied Biosystems).
In addition, for samples analyzed after 2013, the 
sequencing of BRCA1/BRCA2 was performed using the 
Ion Torrent PGM platform. For this, libraries containing 
the PCR product of 14 multiplex PCRs were sequenced 
using the Ion 316 chips, which allow the simultaneous 
analysis of 10 to 12 patients per chip. Data analysis 
was performed using DNAstar Lasergene 10 software, 
following parameters published by Costa et al. [42] and 
subsequently adapted by our group to the following: (1) 
Q call > = 40; (2) depth of coverage > = 100 and, (3) SNP 
% > = 23. All the identified variants were confirmed in a 
new PCR reaction followed by conventional bi-directional 
sequencing (Sanger).
The analysis of BRCA1 and BRCA2 rearrangements 
was performed with the Multiplex Ligation-dependent 
Probe Amplification Kit (MLPA) according to the 
manufacturer’s protocol. For the presence of the 
c.156_157ins Alu at BRCA2 gene, a mutation-specific 
PCR was performed following protocol described 
elsewhere [37].
Mutations nomenclature and classification
The nomenclature of the identified sequence variants 
was applied following the guidelines of the Human 
Genome Variation Society (HGVS) [43]. The biological 
significance of the variants were verified in databases 
such as Human Genome Mutation Database (HGMD) 
[44], Breast Cancer Information Core (BIC) [45], LOVD 
IARC [46], CLINVAR [47], Universal Mutation Database 
(UMD, actual BRCA Share) [48], LOVD [49] and ARUP 
[50]. Only mutations clearly pathogenic or previously 
classified as such, were included. The Align-GVGD [51], 
Polyphen-2  [52], SIFT [53], MAPP [54] and CADD 
[55]  algorithms were used for the in silico analysis of 
the variants of unknown clinical significance identified. 
All variants classified as VUS or with Conflicting results 
by Clinvar were considered as VUSs. In addition, variants 
with severe disagreement (classified as pathogenic by at 
least one database and benign or likely benign by others) 
were also included. All new variants (missense, in frame 
and splicing), not yet reported in the other databases 
consulted, were also considered VUSs.
Ancestry analysis
In order to assess the genetic ancestry we employed 
a panel of 46 ancestry-informative markers (AIMs) 
selected to efficiently measure population admixture 
proportions of four different continental origins (African, 
European, East Asian and Native American) and that 
proved useful for the estimation of ancestral proportions 
in highly admixed individuals or populations like the 
Brazilian [56, 57]. The 46 AIMs were simply genotyped in 
one multiplex PCR followed by capillary electrophoresis 
as previously described [56]. Making use of published 
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data for 748 individuals from the four continental ancestral 
references [56] plus 214 Brazilian control individuals 
previously characterized by our group [58] we then 
performed a comprehensive ancestry analysis in 341/349 
patients. The clustering software Structure [59] was used 
to run supervised analyses using prior information on 
the origin of reference samples in order to estimate the 
ancestral components of the querying samples. Brazil is 
commonly considered as an essentially tri-hybrid (Native 
American, European, African) admixed population 
[19, 56, 57, 60–63], but there are particular locations in 
the country that harbor significant East Asian communities 
introduced more recently (e.g. São Paulo, Campinas; 
IBGE – Instituto Brasileiro de Geografia e Estatística, 
www.ibge.gov.br). For this reason, and taking into 
consideration the confirmed presence of individuals with 
East Asian ancestry among our patients, we proceeded 
with a conservative approach considering four possible 
ancestral contributors in our dataset (i.e. K = 4). Finally, 
we have performed equivalent analyses with Admixture 
[64] so as to assess the consistency of the ancestry 
estimates obtained with both programs.
Statistical analysis
Statistical analysis was conducted using SPSS 
v.19.0 software (Chicago, IL). The comparisons between 
clinical, molecular and ancestral characteristics employed 
a simple analyses using the Chi-square (or Fisher’s 
exact) test. Differences in ancestry estimates between 
mutated and non-mutated patients were carried out using 
Wilcoxon rank-sum test. The association of ancestry with 
patient characteristics (clinical and histopathological data 
and family history information) were examined with 
Mann-Withney (or Kruskal-Wallis) tests. The level of 
significance considered in all tests was 5%.
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